A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
for Major Depressive Disorder (MDD)
30 locations incl. Chino
Sponsor: Seaport Therapeutics
Sex: All·Age: 18 - 65
Code: NCT07065240·Phase 2·Recruiting·Listed Jul 2025